Drug Trial Radar · NCT05203237
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
Last checked: Nov 19, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Dec 14, 2021
Primary completion
Nov 4, 2024
Study completion Dec 3, 2024
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).
Conditions
- Weight Loss
- NASH
Interventions
VK2735Biological
Administered SC
PlaceboBiological
Administered SC
VK2735 PlaceboDrug
Administered orally
VK2735 DrugDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)Time frame: 8 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Viking Clinical Site
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.